Search Result

Results for "

Bmp2 Inhibitors

" in MedChemExpress (MCE) Product Catalog:

標的別:	AAK1 (8) Anaplastic lymphoma kinase (ALK) (1) Apoptosis (3) c-Myc (2) CDK (1) Cyclin G-associated Kinase (GAK) (3) FGFR (1) Glycosidase (1) JAK (2) Kisspeptin Receptor (2) LIM Kinase (LIMK) (1) MAP3K (1) MEK (1) NF-κB (2) Reactive Oxygen Species (ROS) (2) Reference Standards (2) Ribosomal S6 Kinase (RSK) (1) Src (1) TGF-beta/Smad (3) TGF-β Receptor (1) VEGFR (2) Wnt (1)
研究分野別:	Cancer (8) Cardiovascular Disease (2) Inflammation/Immunology (2) Metabolic Disease (1) Neurological Disease (8)

阻害剤およびアゴニスト

蛍光色素

生化学アッセイ試薬

ペプチド

天然物

Targets Recommended: Serpin

製品番号	製品名	Target	研究分野	構造式

HY-N0316

Mollugin 2 Publications Verification	JAK NF-κB Reactive Oxygen Species (ROS) Apoptosis VEGFR c-Myc	Cancer
Mollugin is an orally active and potent NF-κB inhibitor. Mollugin induces S-phase arrest of HepG2 cells, and increased intracellular reactive oxygen species (ROS) levels. Mollugin induces DNA damage in HepG2 cells, as well as an increase in the expression of p-H2AX. Mollugin shows anti-cancer effect by inhibiting TNF-α-induced NF-κB activation. Mollugin enhances the osteogenic action of BMP-2 (bone morphogenetic protein 2) via the p38-Smad signaling pathway .

HY-P0254

Kisspeptin-10, human 1 Publications Verification	Kisspeptin Receptor	Cardiovascular Disease Cancer
Kisspeptin-10, human is a potent vasoconstrictor and inhibitor of angiogenesis. Kisspeptin-10, human acts as a tumor metastasis suppressor via its receptor GPR54. Kisspeptin-10-GPR54 system plays an important role in embryonic kidney development. Kisspeptin-10/GPR54 signaling induces osteoblast differentiation via NFATc4-mediated BMP2 expression .

HY-123940

SGC-AAK1-1 1 Publications Verification	Wnt AAK1	Cancer
SGC-AAK1-1, a chemical probe, is a potent and selective AAK1 (AP2 associated kinase 1) inhibitor with an IC₅₀ of 270 nM and a K_i of 9 nM. SGC-AAK1-1 also potently inhibits BMP2K. SGC-AAK1-1 is used to study Wnt pathway related to AAK1 .

HY-136848

SM1-71	MAP3K Src FGFR Ribosomal S6 Kinase (RSK) LIM Kinase (LIMK)	Cancer
SM1-71 (compound 5) is a potent TAK1 inhibitor, with a K_i of 160 nM, it also can covalently inhibit MKNK2, MAP2K1/2/3/4/6/7, GAK, AAK1, *BMP2K, MAP3K7, MAPKAPK5, GSK3A/B, MAPK1/3, SRC, YES1, FGFR1, ZAK (MLTK), MAP3K1, LIMK1* and RSK2. SM1-71 can inhibit proliferation of multiple cancer cell lines .

HY-135871

BMT-124110	AAK1	Neurological Disease
BMT-124110 is a potent, selective AAK1 inhibitor with an IC₅₀ of 0.9 nM. BMT-124110 shows antinociceptive activity. BMT-090605 inhibits BMP-2-inducible protein kinase (BIKE) and Cyclin G-associated kinase (GAK) with IC₅₀s of 17 and 99 nM, respectively .

HY-173149

CDD-2789	Anaplastic lymphoma kinase (ALK) TGF-beta/Smad TGF-β Receptor	Cancer
CDD-2789 is a potent and selective ALK2 inhibitor with an IC₅₀ 0.54 μM and a K_d of 2.1 nM, respectively. CDD-2789 exhibits >120-fold selectivity over ALK3/5/6. CDD-2789 reduces activin A- and *BMP2*-induced SMAD1/5 phosphorylation in fibroblasts. CDD-2789 can be used for ALK2-related cancer research .

HY-101290A

BMT-090605 hydrochloride	Cyclin G-associated Kinase (GAK) AAK1	Neurological Disease
BMT-090605 hydrochloride is a potent, selective the adapter protein-2 associated kinase 1 (AAK1) inhibitor with an IC₅₀ value of 0.6 nM. BMT-090605 hydrochloride shows antinociceptive activity. BMT-090605 hydrochloride inhibits BMP-2-inducible protein kinase (BIKE) and Cyclin G-associated kinase (GAK) with IC₅₀ values of 45 nM and 60 nM, respectively. BMT-090605 hydrochloride can be used for the research of neuropathic pain .

HY-120179

LP-922761 1 Publications Verification	AAK1	Neurological Disease
LP-922761 is a potent, selective and orally active adapter protein-2 associated kinase 1 (AAK1) inhibitor with IC₅₀s of 4.8 nM and 7.6 nM in enzyme and cell assays, respectively. LP-922761 also inhibits BMP-2-inducible protein kinase (BIKE) with an IC₅₀ of 24 nM. LP-922761 exhibits no significant activity at cyclin G-associated kinase (GAK), opioid, adrenergic α2 or GABAa receptors .

HY-P0254A

Kisspeptin-10, human TFA 1 Publications Verification	Kisspeptin Receptor	Cardiovascular Disease Cancer
Kisspeptin-10, human TFA is a potent vasoconstrictor and inhibitor of angiogenesis. Kisspeptin-10, human TFA acts as a tumor metastasis suppressor via its receptor GPR54. Kisspeptin-10-GPR54 system plays an important role in embryonic kidney development. Kisspeptin-10/GPR54 signaling induces osteoblast differentiation via NFATc4-mediated BMP2 expression .

HY-142042

3-Hydroxy-4-carboxyalkylamidino-5-arylamino-isothiazoles	MEK TGF-beta/Smad	Neurological Disease Inflammation/Immunology Cancer
3-Hydroxy-4-carboxyalkylamidino-5-arylamino-isothiazoles is an inhibitor for bone morphogenetic protein 2 (BMP2) with an IC₅₀ of 2.2 μM. 3-Hydroxy-4-carboxyalkylamidino-5-arylamino-isothiazoles is inhibitor for mitogen-activated protein kinase 1 (MEK1). 3-Hydroxy-4-carboxyalkylamidino-5-arylamino-isothiazoles exhibits anti-inflammatory and neuroprotective activity in EAE mouse model .

HY-N0946

(-)-Pinoresinol 4-O-glucoside (-)-Pinoresinol 4-O-β-D-glucopyranoside	Glycosidase	Metabolic Disease
(-)-Pinoresinol 4-O-glucoside ((-)-Pinoresinol 4-O-β-D-glucopyranoside) is a potent and orally active α-glucosidase inhibitor with an IC₅₀ value of 48.13 µM. (-)-Pinoresinol 4-O-glucoside increases cell migration and early differentiation of pre-osteoblasts. (-)-Pinoresinol 4-O-glucoside increases protein level of BMP2, p-Smad1/5/8, RUNX2. (-)-Pinoresinol 4-O-glucoside attenuates oxidative stress, hyperglycemia and hepatic toxicity. (-)-Pinoresinol 4-O-glucoside has the potential for the research of osteoporosis and periodontal disease .

HY-162653

SGC-CDKL2/AAK1/BMP2K-1		Others
SGC-CDKL2/AAK1/BMP2K-1 (Compound 9) is a potent and selective CDKL2 (Cyclin-dependent kinase-like 2) inhibitor with an IC₅₀ value of 460 nM. CDKL2 is involved in various biological processes such as tumorigenesis, development, and viral infections. SGC-CDKL2/AAK1/BMP2K-1 serves as a powerful tool for studying the biological functions of CDKL2 and holds promise for research in fields related to cancer, infections, and other diseases .

HY-101290

BMT-090605	AAK1 Cyclin G-associated Kinase (GAK)	Neurological Disease
BMT-090605 is a potent, selective the adapter protein-2 associated kinase 1 (AAK1) inhibitor with an IC₅₀ value of 0.6 nM. BMT-090605 shows antinociceptive activity. BMT-090605 inhibits BMP-2-inducible protein kinase (BIKE) and Cyclin G-associated kinase (GAK) with IC₅₀ values of 45 nM and 60 nM, respectively. BMT-090605 can be used for the research of neuropathic pain .

HY-N0316R

Mollugin (Standard)	JAK Reference Standards NF-κB Reactive Oxygen Species (ROS) Apoptosis VEGFR c-Myc	Cancer
Mollugin (Standard) is the analytical standard of Mollugin. This product is intended for research and analytical applications. Mollugin is an orally active and potent NF-κB inhibitor. Mollugin induces S-phase arrest of HepG2 cells, and increased intracellular reactive oxygen species (ROS) levels. Mollugin induces DNA damage in HepG2 cells, as well as an increase in the expression of p-H2AX. Mollugin shows anti-cancer effect by inhibiting TNF-α-induced NF-κB activation. Mollugin enhances the osteogenic action of BMP-2 (bone morphogenetic protein 2) via the p38-Smad signaling pathway .

HY-135871A

BMT-124110 formic	AAK1	Neurological Disease
BMT-124110 formic is a potent, selective AAK1 inhibitor, with an IC₅₀ of 0.9 nM. BMT-124110 shows antinociceptive activity. BMT-124110 formic inhibits BMP-2-inducible protein kinase (BIKE) and Cyclin G-associated kinase (GAK) with IC₅₀s of 17 and 99 nM, respectively .

HY-126675G

AS2863619	CDK TGF-beta/Smad Apoptosis	Inflammation/Immunology
AS2863619 GMP is AS2863619 (HY-126675) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. AS2863619 is an orally active CDK8/19 inhibitor that also inhibits *BMP2, MDA5* and RIG-I receptors. AS2863619 targets Stat5a-CDK8/19 to promote the differentiation of CD4 ⁺ T cells into regulatory T cells and induce FOXP3 expression, thereby restoring immune homeostasis and establishing transplant immune tolerance. AS2863619 also enhances the *BMP2/SMAD* signaling pathway to promote osteogenic differentiation and inhibit adipogenic differentiation. AS2863619 exerts osteoprotective effects by alleviating inflammation-induced impairment of osteogenic function and inducing neutrophil apoptosis (apoptosis). AS2863619 can be applied to research in related fields such as periodontitis-induced bone defects .

HY-120179A

LP-922761 hydrate	AAK1	Neurological Disease
LP-922761 hydrate is a potent, selective and orally active adapter protein-2 associated kinase 1 (AAK1) inhibitor with IC₅₀s of 4.8 nM and 7.6 nM in enzyme and cell assays, respectively. LP-922761 hydrate also inhibits BMP-2-inducible protein kinase (BIKE) with an IC₅₀ of 24 nM. LP-922761 hydrate shows less activity at cyclin G-associated kinase (GAK), opioid, adrenergic α2 or GABAa receptors .

HY-101290AR

BMT-090605 hydrochloride (Standard)	Cyclin G-associated Kinase (GAK) Reference Standards AAK1	Neurological Disease
BMT-090605 (hydrochloride) (Standard) is the analytical standard of BMT-090605 (hydrochloride) (HY-101290A). This product is intended for research and analytical applications. BMT-090605 hydrochloride is a potent, selective the adapter protein-2 associated kinase 1 (AAK1) inhibitor with an IC50 value of 0.6 nM. BMT-090605 hydrochloride shows antinociceptive activity. BMT-090605 hydrochloride inhibits BMP-2-inducible protein kinase (BIKE) and Cyclin G-associated kinase (GAK) with IC50 values of 45 nM and 60 nM, respectively. BMT-090605 hydrochloride can be used for the research of neuropathic pain .

製品番号	製品名	Type

HY-126675G

AS2863619	蛍光色素
AS2863619 GMP is AS2863619 (HY-126675) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. AS2863619 is an orally active CDK8/19 inhibitor that also inhibits *BMP2, MDA5* and RIG-I receptors. AS2863619 targets Stat5a-CDK8/19 to promote the differentiation of CD4 ⁺ T cells into regulatory T cells and induce FOXP3 expression, thereby restoring immune homeostasis and establishing transplant immune tolerance. AS2863619 also enhances the *BMP2/SMAD* signaling pathway to promote osteogenic differentiation and inhibit adipogenic differentiation. AS2863619 exerts osteoprotective effects by alleviating inflammation-induced impairment of osteogenic function and inducing neutrophil apoptosis (apoptosis). AS2863619 can be applied to research in related fields such as periodontitis-induced bone defects .

AS2863619

蛍光色素

AS2863619 GMP is AS2863619 (HY-126675) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. AS2863619 is an orally active CDK8/19 inhibitor that also inhibits BMP2, MDA5 and RIG-I receptors. AS2863619 targets Stat5a-CDK8/19 to promote the differentiation of CD4 ⁺ T cells into regulatory T cells and induce FOXP3 expression, thereby restoring immune homeostasis and establishing transplant immune tolerance. AS2863619 also enhances the BMP2/SMAD signaling pathway to promote osteogenic differentiation and inhibit adipogenic differentiation. AS2863619 exerts osteoprotective effects by alleviating inflammation-induced impairment of osteogenic function and inducing neutrophil apoptosis (apoptosis). AS2863619 can be applied to research in related fields such as periodontitis-induced bone defects .

製品番号	製品名	Type

HY-126675G

AS2863619	生化学アッセイ試薬
AS2863619 GMP is AS2863619 (HY-126675) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. AS2863619 is an orally active CDK8/19 inhibitor that also inhibits *BMP2, MDA5* and RIG-I receptors. AS2863619 targets Stat5a-CDK8/19 to promote the differentiation of CD4 ⁺ T cells into regulatory T cells and induce FOXP3 expression, thereby restoring immune homeostasis and establishing transplant immune tolerance. AS2863619 also enhances the *BMP2/SMAD* signaling pathway to promote osteogenic differentiation and inhibit adipogenic differentiation. AS2863619 exerts osteoprotective effects by alleviating inflammation-induced impairment of osteogenic function and inducing neutrophil apoptosis (apoptosis). AS2863619 can be applied to research in related fields such as periodontitis-induced bone defects .

AS2863619

生化学アッセイ試薬

製品番号	製品名	Target	研究分野

HY-P0254

Kisspeptin-10, human 1 Publications Verification	Kisspeptin Receptor	Cardiovascular Disease Cancer
Kisspeptin-10, human is a potent vasoconstrictor and inhibitor of angiogenesis. Kisspeptin-10, human acts as a tumor metastasis suppressor via its receptor GPR54. Kisspeptin-10-GPR54 system plays an important role in embryonic kidney development. Kisspeptin-10/GPR54 signaling induces osteoblast differentiation via NFATc4-mediated BMP2 expression .

HY-P0254A

Kisspeptin-10, human TFA 1 Publications Verification	Kisspeptin Receptor	Cardiovascular Disease Cancer
Kisspeptin-10, human TFA is a potent vasoconstrictor and inhibitor of angiogenesis. Kisspeptin-10, human TFA acts as a tumor metastasis suppressor via its receptor GPR54. Kisspeptin-10-GPR54 system plays an important role in embryonic kidney development. Kisspeptin-10/GPR54 signaling induces osteoblast differentiation via NFATc4-mediated BMP2 expression .

Mollugin 2 Publications Verification	Monophenols Classification of Application Fields Terpenoids Sesquiterpenes Rubiaceae Phenols Plants Disease Research Fields Rubia cordifolia L. Source Classification Cancer	JAK NF-κB Reactive Oxygen Species (ROS) Apoptosis VEGFR c-Myc
Mollugin is an orally active and potent NF-κB inhibitor. Mollugin induces S-phase arrest of HepG2 cells, and increased intracellular reactive oxygen species (ROS) levels. Mollugin induces DNA damage in HepG2 cells, as well as an increase in the expression of p-H2AX. Mollugin shows anti-cancer effect by inhibiting TNF-α-induced NF-κB activation. Mollugin enhances the osteogenic action of BMP-2 (bone morphogenetic protein 2) via the p38-Smad signaling pathway .

(-)-Pinoresinol 4-O-glucoside (-)-Pinoresinol 4-O-β-D-glucopyranoside	Cicer arietinum L. Plants Compositae Saccharides Monosaccharides Source Classification	Glycosidase
(-)-Pinoresinol 4-O-glucoside ((-)-Pinoresinol 4-O-β-D-glucopyranoside) is a potent and orally active α-glucosidase inhibitor with an IC₅₀ value of 48.13 µM. (-)-Pinoresinol 4-O-glucoside increases cell migration and early differentiation of pre-osteoblasts. (-)-Pinoresinol 4-O-glucoside increases protein level of BMP2, p-Smad1/5/8, RUNX2. (-)-Pinoresinol 4-O-glucoside attenuates oxidative stress, hyperglycemia and hepatic toxicity. (-)-Pinoresinol 4-O-glucoside has the potential for the research of osteoporosis and periodontal disease .

Mollugin (Standard)	Structural Classification Monophenols Terpenoids Sesquiterpenes Rubiaceae Phenols Plants Rubia cordifolia L. Source Classification	JAK Reference Standards NF-κB Reactive Oxygen Species (ROS) Apoptosis VEGFR c-Myc
Mollugin (Standard) is the analytical standard of Mollugin. This product is intended for research and analytical applications. Mollugin is an orally active and potent NF-κB inhibitor. Mollugin induces S-phase arrest of HepG2 cells, and increased intracellular reactive oxygen species (ROS) levels. Mollugin induces DNA damage in HepG2 cells, as well as an increase in the expression of p-H2AX. Mollugin shows anti-cancer effect by inhibiting TNF-α-induced NF-κB activation. Mollugin enhances the osteogenic action of BMP-2 (bone morphogenetic protein 2) via the p38-Smad signaling pathway .

オンラインお問い合わせ

入力情報は安全に管理されます. ※ 必須入力項目.

日本の代理先をお選びくださいナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
タイトル			国或いは地域 *
お名前 *			組纖名 *
デパートメント *
メールアドレス *			製品名 *
製品番号			カスタマ需要量 *
電話番号 *
必ず会社名を記載ください。個人への返信は行いません。
備考

バルクお問い合わせ

Inquiry Information

製品名:
製品番号:
数量:
MCE 日本正規代理店:

お名前
メール *

	Sorry, but the email address you supplied was invalid.